Xeltis secures nearly €50m from the European Investment Bank (EIB) and existing shareholders to advance aXess, its vascular access conduit to the market
- Up to €37.5m investment from the EIB, consisting of €10m upfront with optionality to further increase by an additional €27.5m
- €10m investment from existing shareholders including EQT Life Sciences (EQT) and Invest-NL
- Follows the announcement of excellent EU pivotal trial data highlighting the transformative potential of aXess in hemodialysis treatment
- European market approval and US pre-market approval of aXess expected in 2026
EINDHOVEN, The Netherlands, 2 December 2025 – Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announces that it has secured nearly €50m of new financing, consisting of up to €37.5m from the EIB, supported under the European Commission’s Invest EU programme, and €10m from existing investors, including EQT, investing from its LSP Health Economics Fund 2, and Invest-NL. The proceeds raised will be used to advance aXess into commercialization, including upscaling production and hiring, and supporting the continued development of its broader pipeline.
